Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Compounding Pharmacies On Ribavirin, Propulsid Versions

Executive Summary

A recent spate of enforcement actions by FDA against compounding pharmacies includes citations for compounded versions of ribavirin and Propulsid

You may also be interested in...



Wyeth Urges Halt to Hormone Compounding, Questioning Its Safety

Wyeth's citizen petition to the FDA urging it to stop compounding pharmacists from producing "bioidentical hormone replacement therapy" focuses on safety concerns about the practice

Wyeth Urges Halt to Hormone Compounding, Questioning Its Safety

Wyeth's citizen petition to the FDA urging it to stop compounding pharmacists from producing "bioidentical hormone replacement therapy" focuses on safety concerns about the practice

FDA Oversight Of Rx Compounding Should Increase, GAO Study Suggests

Increased FDA oversight of pharmacy compounding may be necessary due to state budgetary constraints, an Oct. 23 General Accounting Office report suggests

UsernamePublicRestriction

Register

LL1135975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel